Carisma Therapeutics, Inc.

OTCPK:CARM Stock Report

Market Cap: US$67.0k

Carisma Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure3.3yrs

Recent management updates

Recent updates

Analysis Article • Mar 28

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry

You may think that with a price-to-sales (or "P/S") ratio of 0.7x Carisma Therapeutics, Inc. ( NASDAQ:CARM ) is...
Analysis Article • Dec 06

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shares have had a horrible month, losing 28% after a relatively good period...
Analysis Article • Sep 02

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • May 12

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) just released its latest quarterly report and things are not looking great...
Analysis Article • Apr 19

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

The Carisma Therapeutics, Inc. ( NASDAQ:CARM ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Mar 26

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 21

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shareholders won't be pleased to see that the share price has had a very...
Analysis Article • Dec 07

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

To the annoyance of some shareholders, Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shares are down a considerable 27% in...
Analysis Article • Nov 12

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

The analysts covering Carisma Therapeutics, Inc. ( NASDAQ:CARM ) delivered a dose of negativity to shareholders today...
Analysis Article • Oct 05

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jun 15

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Carisma Therapeutics has no CEO, or we have no data on them.

Board Members

NamePositionTenureCompensationOwnership
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Sanford Zweifach
Independent Chairman of the Board3.3yrsUS$143.23k0.00099%
$ 0.7
Hyam Levitsky
Member of Scientific Advisory Boardno datano datano data
Carl June
Member of Scientific Advisory Boardno datano datano data
Nina Bhardwaj
Member of Scientific Advisory Board5.9yrsno datano data
Steven Kelly
Director3.3yrsUS$1.72m0%
$ 0
Scott L. Friedman
Member of Scientific Advisory Board1.8yrsno datano data
Marella Thorell
Independent Director2yrsUS$81.48k0%
$ 0
Lisa Coussens
Member of Scientific Advisory Boardno datano datano data
Prasad Adusumilli
Member of Scientific Advisory Board5.9yrsno datano data
Sohanya Cheng
Independent Director1.7yrsUS$39.29k0%
$ 0
Lin Guey
Member of Scientific Advisory Board3.3yrsno datano data
3.3yrs
Average Tenure
64.5yo
Average Age

Experienced Board: CARM's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 21:41
End of Day Share Price 2026/06/10 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Carisma Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Suranjit MukherjeeBTIG
Naureen QuibriaCapital One Securities, Inc.